 |
|
 |
Cancer |
|
|
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
Publication Date September 2007
Publisher Datamonitor
Product Type Report
Pages 503
ISBN Number not applicable
Product Code DAT030
|
|
|
Summary
Introduction
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
Scope
- Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for 17 tumor types
- Seven major pharmaceutical sales forecasts for Phase III pipeline products through to 2016 with product-specific assumptions
- Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication
- Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs
Highlights
The current solid tumor pipeline contains at least 707 unique agents, 9% of which are in late-phase development. These products cover a vast array of anticancer drug classes, including antihormonal therapies, cytotoxics, gene therapies, immunotherapies, photodynamic therapies, radiotherapeutics, targeted therapies and therapeutic vaccines.
The late-phase pipeline contains equal amounts of cytotoxics and targeted therapies. The Phase I and II pipelines contain more than twice as many targeted therapies as cytotoxics. As such, it is clear that increasing diversity in terms of drug targets may result in greater treatment options in years to come if positive clinical data is generated.
Despite high levels of unmet need and relatively healthy pipelines for most indications, no major breakthroughs are expected by current late-phase products aside from incremental increases in efficacy and reduced toxicity. This indicates a heavy reliance on the earlier-phase pipeline for further breakthroughs in terms of treatment of solid tumors.
Reasons to Purchase
- Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2016 and Datamonitor drug assessment
- Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction
- Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products
|
Content
- Chapter 1 Executive Summary
- Scope of the analysis
- Datamonitor insight into the cancer market
- Related reports
- Upcoming reports
- Chapter 2 Pipeline Overview and Dynamics
- Pipeline overview
- Novel agents
- Marketed products
- Pipeline by developmental phase and indication
- The big four tumor types are still the most popular R&D targets, although brain cancer, melanoma, ovarian cancer, pancreatic cancer and RCC are increasing in relevance
- Pipeline split by phase
- Only 9% of the current pipeline is in late-phase development
- Pipeline by drug class
- Novel therapies constitute a greater proportion of the pipeline in the early phases of development
- Solid tumor commonalities
- to show applicability for use in numerous indications, a pipeline drug must affect a target that is expressed across a range of tumor types
- Key companies involved in the solid tumor pipeline
- The top three companies in terms of marketed and pipeline drugs for solid tumors are Pfizer, AstraZeneca and Novartis
- Pfizer
- AstraZeneca
- Novartis
- Chapter 3 R&d Approach
- Classification of pipeline products
- Cytotoxics
- Antihormonal therapies
- Molecular targeted therapies
- Single-target signal transduction inhibitors
- Angiogenesis inhibitors
- Apoptosis inducers
- Cell cycle inhibitors
- Multi-targeted inhibitors
- Epigenetic modulators
- Immunotherapeutic agents
- Oncology clinical trial design
- Patient selection
- Increasingly significant in the era of targeted treatment
- Clinical trial duration
- Sufficient follow-up is necessary to establish true clinical benefit
- The advent of novel therapies
- Diversity of targeted therapies will require an evolution in clinical trial design
- Clinical trial endpoints in oncology
- Most oncology clinical trials designate multiple endpoints
- Survival
- Quality of life
- Tumor response rates
- Toxicity
- Time to tumor progression
- Chapter 4 Bladder Cancer
- Overview of bladder cancer
- Definition
- Bladder cancer remains a common tumor type in males
- Epidemiology
- Incidence of bladder cancer will rise due to an increase in industrialization, lifestyle factors and an ageing population
- Mortality from bladder cancer is very low in the early stages, however, rises dramatically once the tumor spreads
- Treatment of bladder cancer
- Unmet need in bladder cancer
- Summary of unmet needs
- Increase early diagnosis to enhance survival
- Agents with better routes of administration in comparison with intravesical therapy
- A better 'standard' for advanced disease with less toxicity is needed
- Salvation of the bladder is the ideal
- Pipeline overview
- Spectrum Pharmaceuticals' EOquin (apaziquone)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Some satisfaction of unmet needs will occur, however, further research is needed in advanced disease
- Chapter 5 Primary Brain Cancer
- Overview of primary brain cancer
- Definition
- Glioma is the most common type of primary brain cancer
- Epidemiology
- Incidence of brain cancer is rising in line with the ageing population
- Mortality from brain cancer is very high in comparison to its incidence
- Treatment of primary brain cancer
- Unmet need in primary brain cancer
- Summary of unmet needs
- More effective chemotherapy options needed
- Blood-brain barrier may prove an obstacle to overcome
- Need for neuroprotective therapy
- Pipeline overview
- Ark Therapeutics' Cerepro (sitimagene ceradenovec)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Peregrine Pharmaceuticals's Cotara (131I-chTNT-1/B)
- Drug overview
- Clinical trial data
- Datamonitor comments
- YM Biosciences/Biocon Biopharmaceuticals' Theraloc (nimotuzumab)
- Drug overview
- Clinical trial data
- Datamonitor comments
- NeoPharm's cintredekin besudotox
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Temodar will retain its leading status for some time to come in the primary brain cancer market
- Chapter 6 Breast Cancer
- Overview of breast cancer
- Definition
- Breast cancer remains the most common cancer and second most common cause of cancer-related death in women worldwide
- Epidemiology
- Incidence of breast cancer will continue to rise as lifestyles associated with risk factors are increasingly adopted, rates of screening increase in some countries and in line with the ageing population
- While mortality rates are low in comparison to incidence, absolute mortality shows breast cancer remains a leading cause of death in women
- Treatment of breast cancer
- Unmet need in breast cancer
- Summary of unmet needs
- Effective treatment for metastatic disease still remains elusive
- A wider range of treatment options is necessary for hormone receptor-negative patients
- Elderly patients remain underserved in terms of treatment options
- More convenient and better tolerated therapies are needed
- Earlier diagnosis improves prognosis but awareness must remain high
- Pipeline overview
- Bristol-Myers Squibb's ixabepilone (BMS-247550)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Sonus Pharmaceuticals/Bayer Schering's Tocosol paclitaxel (emulsion paclitaxel)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Eisai's eribulin (E7389)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Sanofi-Aventis's larotaxel (XRP-9881)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Ixabepilone has a real chance of fulfilling some unmet need in the breast cancer market
- Chapter 7 Cervical Cancer
- Overview of cervical cancer
- Definition
- Cervical cancer constitutes 17% of all gynecological tumors
- Epidemiology
- Incidence will rise in line with the ageing population
- Mortality is relatively high in comparison to incidence of cervical cancer given its propensity for early diagnosis
- Treatment of cervical cancer
- Unmet need in cervical cancer
- Summary of unmet needs
- A major healthcare burden in developing countries
- Less invasive surgery is required for early-stage tumors
- Better systemic therapy is required for metastatic and recurrent disease
- More large-scale, randomized clinical trials are necessary to define optimal treatment strategies across cervical cancer
- The cervical cancer pipeline is relatively sparse
- Pipeline overview
- Sanofi-Aventis/National Cancer Institute's Tirazone (tirapazamine)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Unmet needs are unlikely to be fulfilled by the current pipeline
- Chapter 8 Colorectal Cancer
- Overview of colorectal cancer
- Definition
- Colorectal cancer is the third most common tumor type and cause of cancer-related death in both men and women
- Epidemiology
- Incidence continues to rise with an increase in prevalence of risk factors and the ageing population
- Mortality from colorectal cancer is relatively high due to a tendency for later diagnosis
- Treatment of colorectal cancer
- Unmet need in colorectal cancer
- Summary of unmet needs
- Lack of identifiable risk factors and effective screening tools
- Prognosis remains poor, despite significant advances in therapy
- A high rate of disease recurrence illustrates the need for more effective therapies
- Pipeline overview
- Pro-Pharmaceuticals' Davanat (drug delivery system)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Adventrx Pharmaceuticals's Cofactor (Anx-510)
- Drug overview
- Clinical trial data
- Datamonitor comments
- AstraZeneca's Recentin (cediranib, AZD-2171)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Improvements in efficacy and prognosis are unlikely to be made by current late-phase pipeline products
- Chapter 9 Head and Neck Cancer
- Overview of head and neck cancer
- Definition
- Head and neck cancers comprise around 6% of all tumors worldwide
- Epidemiology
- Incidence will continue to rise in line with the ageing population
- Mortality is high due to frequent late-stage diagnosis and lack of effective treatments
- Treatment of head and neck cancer
- Unmet need in head and neck cancer
- Summary of unmet needs
- Currently available therapies induce modest response rates
- High level of treatment-related morbidity and poor quality of life
- Early-stage diagnosis is limited, thereby compromising survival
- High economic burden
- Pipeline overview
- Regulon's Lipoplatin (liposomal cisplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Medarex/Genmab's zalutumumab (HuMax-EGFR)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Cel-Csi's Multikine (Mixture of Naturally Occurring Cytokines)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Viventia Biotech's Proxinium (VB4-845)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Introgen Therapeutics' Advexin (contusugene, INGN-201)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Introgen Therapeutics' INGN-241
- Drug overview
- Clinical trial results
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Superiority over current standard therapies is unlikely to be shown by the current pipeline
- Chapter 10 Hepatocellular Carcinoma
- Overview of HCC
- Definition
- Hepatitis is a known risk factor for HCC
- Epidemiology
- Japan accounts for nearly half of all new HCC cases in the seven major markets due to a high prevalence of hepatitis
- Mortality from HCC is high, although prognosis is steadily improving
- Treatment of HCC
- Unmet need in HCC
- Summary of unmet needs
- Curbing the increasing incidence of HCC
- Better systemic therapy is required
- Clinical trials are currently poorly designed
- HCC suffers from a relatively modest R&D interest
- Pipeline overview
- Phoenix Pharmacologics' Hepacid (pegylated arginine)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- despite impending approval of Nexavar, effective systemic therapies are still required
- Chapter 11 Melanoma
- Overview of melanoma
- Definition
- Melanoma is the least common type of skin cancer, although the most potentially fatal
- Epidemiology
- Incidence of melanoma will continue to increase due to increasing exposure of patients to UV light
- Mortality from melanoma is relatively low in comparison to its incidence due to a high rate of early diagnosis
- Treatment of melanoma
- Unmet need in melanoma
- Summary of unmet needs
- Current therapeutics have a high risk to benefit ratio
- over the past three decades there have been few significant advances in pharmacotherapy for metastatic disease
- Early diagnosis is the key to curative treatment
- Gene profiling will help individualize treatment approaches
- Pipeline overview
- Luitpold Pharmaceuticals' Taxoprexin (DHA paclitaxel)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Vical's Allovectin-7 (velimogene aliplasmid)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Bristol-Myers Squibb/Medarex's ipilimumab (MDX-010)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pfizer's tremelimumab (CP-675206)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Genta's Genasense (oblimersen)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Progenics's GMK (GM2-KLH)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Antigenics's Oncophage (vitespen)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Bristol-Myers Squibb/Medarex's MDX-1379
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- The turbulent developmental history of late-phase pipeline candidates for melanoma means unmet needs are unlikely to be fulfilled in the near future
- Chapter 12 Mesothelioma
- Overview of mesothelioma
- Definition
- Mesothelioma is almost always caused by sustained exposure to asbestos
- Epidemiology
- Forecast incidence is difficult to predict for mesothelioma, although the cancer is relatively rare
- Survival rates for mesothelioma have improved minimally over the years
- Treatment of mesothelioma
- Unmet need in mesothelioma
- Summary of unmet needs
- Increasing incidence and need for earlier diagnosis
- Low rate of curative surgery
- Lack of approved therapies and low R&D interest
- Pipeline overview
- Alfacell Corp's Onconase (ranpirnase)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Onconase meets some unmet needs in terms of providing much needed alternative treatment options
- Chapter 13 Non-Small Cell Lung Cancer
- Overview of NSCLC
- Definition
- Lung cancer is the leading cause of cancer-related deaths in both men and women
- Epidemiology
- The ageing population will drive a rise in NSCLC incidence in the future
- Nsclc Has A Very High Mortality Rate
- Treatment of NSCLC
- Unmet need in NSCLC
- Summary of unmet needs
- Improved efficacy is required in the treatment of both early-stage and advanced NSCLC
- There is a need for effective second-line treatments
- Novel therapies with improved toxicity profiles are required
- Treatment of NSCLC is in need of an overall refinement
- Clinical trial design should be re-assessed for the appropriate evaluation of targeted therapies
- Pipeline overview
- Cba Research's Cbt-1
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pierre Fabre/Bristol-Myers Squibb's Javlor (vinflunine)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Regulon's Lipoplatin (liposomal cisplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Luitpold Pharmaceuticals's Taxoprexin (DHA paclitaxel)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Cell Therapeutics' Xyotax (paclitaxel poliglumex)
- Drug overview
- Clinical trial data
- Datamonitor comments
- AstraZeneca's Recentin (cediranib, AZD-2171)
- Drug overview
- Clinical trial data
- Datamonitor comments
- AstraZeneca's Zactima (vandetanib, ZD6474)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Regeneron/Sanofi-Aventis aflibercept (VEGF Trap)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Biomira/Merck Serono's Stimuvax (BLP-25)
- Drug overview
- Clinical trial data
- Datamonitor comments
- GlaxoSmithKline's MAGE-A3 ASCI (GSK-1572932A)
- Drug overview
- Clinical trial results
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Unmet needs are unlikely to be fulfilled by the current pipeline
- Chapter 14 Ovarian Cancer
- Overview of ovarian cancer
- Definition
- Ovarian cancer is the most frequent cause of cancer-related death from gynecological malignancies
- Epidemiology
- Ovarian cancer is a disease primarily of postmenopausal women, therefore incidence will continue to rise in line with the ageing population
- Mortality from ovarian cancer is relatively high in comparison with its incidence due to a high rate of diagnosis at Stage III disease
- Treatment of ovarian cancer
- Unmet need in ovarian cancer
- Summary of unmet needs
- Earlier rates of diagnosis are needed
- Less invasive surgical techniques are required
- More effective systemic therapies are needed across multiple lines of treatment
- Increase level of R&D interest
- Pipeline overview
- BioNumerik's Karenitecin (BNP-1350)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Cell Therapeutics/Novartis's Xyotax (paclitaxel poliglumex)
- Drug overview
- Clinical trial data
- Datamonitor comments
- PharmaMar/Johnson & Johnson's Yondelis (trabectedin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Novartis's patupilone (EPO-906)
- Drug overview
- Clinical trial data
- Datamonitor comments
- ViRexx Medical Corp/Unither Pharmaceuticals' OvaRex (oregovomab)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Telik's Telcyta (canfosfamide, TLK-286)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Marshall Edward's phenoxodiol
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Unmet needs in ovarian cancer will be fulfilled to some extent by means of providing numerous alternative treatment options
- Chapter 15 Pancreatic Cancer
- Overview of pancreatic cancer
- Definition
- Pancreatic cancer represents a major health issue in the developed world
- Epidemiology
- Absolute incidence of pancreatic cancer correlates to population size, therefore incidence will continue to rise as a reflection of the ageing population
- Mortality from pancreatic cancer is nearly equal to its incidence
- Treatment of pancreatic cancer
- Unmet need in pancreatic cancer
- Summary of unmet need
- Associated with exceptionally poor survival rates
- Earlier rates of diagnosis are desperately needed in order to boost survival
- A lack of effective systemic therapies exists, therefore an increased level of R&D interest is needed
- Pipeline overview
- Sanofi-Aventis's larotaxel (XRP-9881)
- Drug overview
- Clinical trial data
- Datamonitor comments
- GenVec's TNFerade (TNF-alpha gene therapy)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pfizer's axitinib (AG-13736)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Pharmexa/GemVax's GV-1001
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- All four late-phase pipeline products show some potential to fulfill unmet needs in the pancreatic cancer market
- Chapter 16 Prostate Cancer
- Overview of prostate cancer
- Definition
- Prostate cancer remains the most common cancer and second cause of cancer-related death in men worldwide
- Epidemiology
- Incidence of prostate cancer continues to rise with advances in screening procedures
- Mortality from prostate cancer is relatively low given the high propensity for early diagnosis
- Treatment of prostate cancer
- Unmet need in prostate cancer
- Summary of unmet needs
- Side effects from antihormonal therapies may affect compliance
- Alternative treatment options are needed for hormone-refractory patients
- Greater R&D interest is needed in terms of innovative therapies
- Pipeline overview
- Dendreon's Provenge (sipuleucel-T)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Ferring/Astellas's degarelix
- Drug overview
- Clinical trial data
- Datamonitor comments
- Novacea/Schering-Plough's Asentar (calcitriol, DN-101)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Spectrum Pharmaceuticals/GPC Biotech's Orplatna (satraplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Sanofi-Aventis's XRP-6258
- Drug overview
- Clinical trial data
- Datamonitor comments
- Abbott's Xinlay (atrasentan)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Cell Genesys's GVAX (CG-8123)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Prostate cancer's high patient potential means R&D interest is relatively high and unmet needs have a higher chance of being fulfilled
- Chapter 17 Renal Cell Carcinoma
- Overview of renal cell carcinoma
- Definition
- Renal cell carcinoma has formed a popular R&D indication in recent times
- Epidemiology
- Incidence of renal cell carcinoma will continue to rise in line with the ageing population, increasing rates of obesity and more frequent diagnosis following imaging procedures
- Mortality is high in late-stage RCC patients
- Treatment of RCC
- Unmet need in RCC
- Summary of unmet need
- Adjuvant therapy to prevent relapse following surgery in Stage I-III patients
- More systemic therapies required to provide options in later lines of treatment
- Non-clear cell RCC subtypes must be the focus of future therapies
- Pipeline overview
- Wilex's Rencarex (WX-G250)
- Drug overview
- Clinical trial data
- Datamonitor comments
- GlaxoSmithKline's pazopanib (GW-786034)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Antigenics' Oncophage (vitespen)
- Drug overview
- Clinical trial data
- Datamonitor comments
- LipoNova's Reniale
- Drug overview
- Clinical trial data
- Datamonitor comments
- Oxford Biomedica's TroVax (MVA-h5T4)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Potential adjuvant therapies are in development, while the need for multiple products in later treatment settings may also be fulfilled
- Chapter 18 Sarcomas
- Overview of sarcoma
- Definition
- Sarcomas represent a diverse group of malignancies
- Epidemiology
- Given the numerous subtypes of sarcoma, crude incidence rates are not readily available
- Evolution of multimodality treatment for sarcomas of the bone has improved survival, while early diagnosis of soft tissue sarcoma allows for relatively high survival
- Treatment of sarcoma
- Sarcoma of the bone
- Soft tissue sarcoma
- Unmet need in sarcoma
- Summary of unmet need
- Better classification methods are needed
- Greater range of treatment options following surgery and more efficacious agents for advanced disease are necessary
- Pipeline overview
- IDM Pharma's Junovan (liposomal mifamurtide)
- Drug overview
- Clinical trial data
- Datamonitor comments
- PharmaMar/Johnson & Johnson's Yondelis (trabectedin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Novartis's Tasigna (nilotinib)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Current pipeline drugs will go some way toward satisfying the need for a greater range of treatment options in sarcoma
- Chapter 19 Small Cell Lung Cancer
- Overview of SCLC
- Definition
- SCLC is the most aggressive lung tumor, although the most responsive to chemotherapy and radiotherapy
- Epidemiology
- Incidence of SCLC is decreasing in part due to declining rates of cigarette smoking
- Five-year survival rates for SCLC are poor, although slowly improving
- Treatment of SCLC
- Unmet need in SCLC
- Summary of unmet needs
- Need for earlier diagnosis
- Strong association with smoking
- Low rate of curative surgery
- Lack of efficacious systemic therapies
- Low R&D interest
- Pipeline overview
- Poniard Pharmaceuticals' Nexplatin (picoplatin)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Nexplatin could fulfill some unmet need in a treatment setting with few alternative treatment options
- Chapter 20 Thyroid Cancer
- Overview of thyroid cancer
- Definition
- Thyroid cancer occurs more frequently in women and at a younger age
- Epidemiology
- Incidence of thyroid cancer is rising due to increasing use of ultrasound to detect small tumors
- Thyroid cancer is one of the least deadly tumor types
- Treatment of thyroid cancer
- Unmet need in thyroid cancer
- Summary of unmet need
- R&D interest is exceedingly low
- Few alternative treatment options exist upon disease recurrence
- Pipeline overview
- Pfizer's axitinib (AG-13736)
- Drug overview
- Clinical trial data
- Datamonitor comments
- Forecasts to 2016
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Axitinib could form a viable therapy where few alternative treatment options exist
- Appendix A
- List of tables
- List of figures
- List of abbreviations
- Methodology
- Datamonitor forecast methodology
- Epidemiology forecasts
- Product forecasts
- Datamonitor drug assessment summary
- Appendix B
- about Datamonitor
- about Datamonitor Healthcare
- Datamonitor Healthcare's therapy area capabilities
- about the Disease analysis team
- Disclaimer
|
|
| Scope |
Expert Insight/Opinion |
|
| Level |
Specific High-level Advice |
|
| Features |
Primary Research Data |
|
| Extra Info |
R&D Pipeline |
|
|
